Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

Chunmiao Zhao1, Yanfang Chu1, Zhaoyun Liang1, Bingying Zhang1, Xuxia Wang1, Xiaona Jing1, Meihua Hao1, Yiqi Wang1, Jia An1, Xingzhe Zhang2, Liguang Sun3* and Junwei Chen1*

Abstract

Background: The development of Systemic lupus erythematosus (SLE) has been associated with the balance of Th17 and Treg cells. IL-2 and rapamycin can influence the populations of both Th17 and Treg cells. However, it is unclear whether low dose of IL-2 and rapamycin can relieve the symptoms of SLE patients and what is the mechanisms. In this study, we aim to analyze the effect of low dose of IL-2 plus rapamycin on the number of Tregs, Th17 cells and the ratio of Th17/Treg cells, as well as to evaluate its therapeutic efficacy in refractory SLE patients.

Result: Fifty refractory SLE patients and 70 healthy controls were enrolled and followed up for 24 weeks. We found that compared with HC, the refractory SLE patients had a lower number of Tregs, a similar number of Th17 cells, but an increased ratio of Th17/Treg. After the treatment, the number of Tregs of the patients at 12th and 24th week was significantly increased. While the number of Th17 cells was unchanged, the ratio of Th17/Treg was significantly decreased at both 6 weeks and 24 weeks. After 6, 12 and 24 weeks of treatment, the SLEDAI score was significantly reduced. The prednisone dosage at 6th, 12th and 24th week post treatment was significantly decreased.

Conclusion: Our results support that the reduction of Tregs and the imbalance of Th17/Treg cells were correlated with the occurrence and development of refractory SLE. Low dose of IL-2 combined with rapamycin was able to restore the number of Tregs and the balance of Th17/Treg cells. As a result, this approach was able to induce immune tolerance and promote disease remission, allowing for the reduction in prednisone dosage.

Trial registration: ChiCTR-IPR-16009451 Registration date: 2016/10/16

Keywords: Systemic lupus erythematosus, IL-2, Rapamycin, Th17 cells, Treg cells
number of Treg cells and maintain immune homeostasis transiently to alleviate disease symptoms in SLE patients [9–13], however, majority of the studies are focused on the short-term effect [13] which is not a feasible long term solution [14]. While rapamycin can inhibit the differentiation of Th17 cells and promote the proliferation and the differentiation of Treg cells, such as in vitro and in vivo in kidney transplant recipients [15], a murine CD4+ T cell transfer model of colitis and an experimental autoimmune encephalomyelitis (EAE) model [16] and CCl4-induced liver fibrosis [17]. Therefore, it is unknown whether low dose of IL-2 combined with rapamycin can increase the number of Tregs and restore the balance of Th17/Treg cells as well as maintain the function long term in SLE patients, although we did a limited primary observation [18]. In this study, we will evaluate the effect of low dose IL-2 and rapamycin on the Treg status and immune balance.

**Methods**

**Patients and healthy controls**

Total 50 patients with refractory SLE, including 47 females and 3 males, were enrolled in the department of Rheumatology, the 2nd Hospital of Shanxi Medical University, from December 2016 to January 2018. A detailed list of characteristics of the patients were shown in Table 1. All the patients were diagnosed according to the classification standard revised by the American College of rheumatology (ACR) in 1997 [19]. Refractory SLE refers to the disease continues, but does not alleviate or worsen in clinical and laboratory indexes after the induction with high-dose glucocorticoid (> 1 mg. Kg-1. D-1) and/or more than 1 cytotoxic drug [20, 21]. We eliminated patients with the complication of serious heart, liver, kidney disease, vital sign instability and contraindications and allergic histories of IL-2 and rapamycin from the study. Patients who are participating in other clinical trials were also eliminated; patients with tumors, infections, pregnancy or lactation, renal insufficiency were further eliminated from the study. Clinical and laboratory data were collected in detail for all patients, and the activity score (SLEDAI) was determined according to literature [22]. Seventy age-matched (35.84 ± 9.40 years) and gender-matched healthy adults were selected as healthy controls, including 59 females and 11 males. All subjects agreed to participate in this study voluntarily and signed the consent form.

**Method**

Low dose of IL-2 (100 WIU, 3-5d/month, subcutaneous injection) and rapamycin (0.5 mg, once every other day, oral) were given to all refractory SLE patients. The following data were collected and analyzed: clinical characteristics, medication status, ESR, and the absolute number and ratio of Th17 and Treg cells. Data for refractory SLE group and healthy control group were compared, and the therapeutic efficacy of low dose of IL-2 plus rapamycin in the treatment of refractory SLE was analyzed.

**Flow cytometry analysis**

Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral blood by Ficoll-Paque PREMIUM 1.077 (GE Healthcare Life Sciences, Pittsburgh, PA) density gradient centrifugation. 2X10⁶ cells were cultured in RPMI 1640 medium with 50 ng/ml PMA, 1 μg/ml ionomycin and 1 μl Golgi Stop for 5 h in a CO₂ incubator at 37 degree. The stimulated cells were stained with FITC- and anti-human CD4 Ab for 30 min at 4 degree. After washing, the cells were incubated with freshly prepared Fixation/Permeabilization solution at 4 degree for 30 min in the dark. After washing, the fixed cells were stained with PE-anti-human IL-17 Ab (560436, BD Pharmingen™) at 4 degree for 30 min in the dark. Then the cells were washed and analyzed by flow cytometry.

**Intracellular staining**

PBMCs were incubated with FITC-anti-hCD4(555346, BD Pharmingen™) and APC-R700 anti-hCD25 Abs(565106,BD Horizon™) at 4 degree for 30 min in the dark. Then cells were treated with 1 ml freshly prepared Fixation/Permeabilization solution at 4 degree for 30 min in the dark, and then stained with PE-anti-human FOXP3 antibody(560046,BD Pharmingen™) at 4 degree for 30 min in the dark, washed with PBS, and detected by a flow cytometer (Calibur, BD, USA). Cells were analyzed with a BD FACSCanto II system (BD Biosciences, San Jose, CA), followed by data analysis using FlowJo 7.6 software (TreeStar, SanCarlos, CA).

**Statistical analysis**

The data were analyzed by SPSS 20.0 statistical software (SPSS Inc., Chicago, IL) and GraphPad Prism 5.0 software (GraphPad Software 5.0, San Diego, CA). Kolmogorov-Smirnov test and Levene’s T test were used for normal test and variance homogeneity analysis. Two-group comparison was performed with student’s t test or the nonparametric...
Mann-Whitney rank-based test. For >2 groups, one-way analysis of variance (ANOVA) or the nonparametric Kruskal-Wallis test was performed, and the pairwise comparison was conducted using the LSD test. Pearson test was used for correlation analysis. P < 0.05 was considered as significantly different.

Results
Decreased Tregs number in the PBMCs of SLE patients
To assess the changes of Tregs and Th17 cells in SLE patients, we analyzed the total cell numbers of these two populations by FACS. We found that while the absolute number of Th17 cells was not significantly different (P = 0.157) between the two groups, the absolute number of Treg cells in refractory SLE patients was significantly lower than that of the healthy controls (P < 0.001). In addition, the ratio of Th17/Treg cells was significantly higher than that of the healthy control group (P < 0.001) (Fig. 1a, b and c).

No correlation between the absolute number of Th17 cells, Treg cells, Th17/Treg ratio, the duration of disease, SLEDAI score and ESR in refractory SLE patients
Through pearson test analysis, we did not observe significant correlation of the absolute number of Treg cells, Th17 cells, Th17/Treg ratio with disease duration, SLEDAI score and ESR (Table 2).

Changes in disease activity indicators, Th17, Treg, Th17/Treg, prednison and DMARDs in patients with refractory SLE during the follow-up period
Low-dose IL-2 combined with rapamycin increased Treg cells population in refractory SLE patients
Since it is known that low-dose IL-2 and rapamycin can increase the proportion of Treg cells, we assessed the effect of the combined treatment in patients with refractory SLE. We found that during the follow-up period after treatment, although the absolute number of Th17 cells was unchanged (P = 0.107), the absolute number of Treg cells significantly increased at 12 and 24 weeks (P = 0.015 and P = 0.002). Moreover, the ratio of Th17/Treg significantly decreased at 24 weeks post-treatment (P = 0.007) (Fig. 2a, b and c).

SLEDAI significantly decreased after the treatment of low-dose IL-2 combined with rapamycin
After 24 weeks of treatment, the SLEDAI score was significantly lower than 0 week (P < 0.001) and 6 weeks (P = 0.012). The SLEDAI score at 6th week was lower than 0 week (P = 0.002). The SLEDAI score at 12th week was significantly lower than 0 week (P < 0.001). There was no statistical significance in ESR observed during the follow-up period (P = 0.304) (Fig. 3a and b).

Prednison dosage significantly decreased after the treatment of low-dose IL-2 combined with rapamycin
During the 24-week follow-up period, prednison dosage at 6th, 12th and 24th week was significantly lower than that of 0 week (P = 0.008, P < 0.001 and P < 0.001). The prednison dosage at 12th and 24th week was significantly lower than that of 6th week (P = 0.022 and P = 0.005). By contrast, the DMARDs drug dosage did not decreased (PHCQ = 0.228 and PMMF = 0.290) (Fig. 4a, b and c).

Discussion
The developmental process and mechanism of SLE are highly complicated. Initial studies have shown that SLE is associated with immune disorders caused by the overactive T-cell-dependent B cells. Furthermore, it has been demonstrated that Th17 cells and Treg cells are involved in the pathogenesis of SLE [2, 3].

Th17 cells are a subgroup of CD4⁺T cells producing cytokine IL-17. In the presence of TGF-β and IL-6, Naive T cells express retinoic acid-related orphan nuclear receptor-γt (RORγt) [3] and differentiate into Th17 cells. The differentiation of Th17 cells is regulated by an activated mTOR, a conserved serine/threonine kinase. Tregs are also known as CD4⁺CD25⁺Foxp3⁺ T cells, which are primarily differentiated from native T cells in the presence of TGF-β [23]. Regulated by the STAT5 signaling pathway, Tregs play an important role in maintaining immune balance and regulating immune tolerance. A number of studies have shown that Th17 cells are significantly increased in both SLE mice and patients [24]. In the target organs of SLE patients, the number of Th17 cells as well as the expression level of IL-17 in peripheral blood are increased, which is correlated with disease activity [25]. This suggests that Th17 cells and IL-17 production are associated with the progression of SLE. Recently, many clinical studies on human autoimmune diseases, animal models and SLE patients revealed the decrease of Treg cells number is closely related to the disease occurrence [3, 26]. In this study, we also found that in comparison with the healthy control group, refractory SLE patients have a reduced Treg number in peripheral blood, which is consistent with the results from Noack’s study [26], suggesting that the pathogenesis of SLE may be related to the destruction of autoimmune tolerance caused by a decrease of Treg. Yang and colleagues found that the underlying pathogenesis of lupus mice might be induced by the imbalanced ratio of Th17/Tregs and cytokines in the microenvironment [27]. Consistently, Doff and colleagues demonstrated that the ratio of Th17/regulatory T cells in patients with the remission of SLE was higher than that in healthy controls [28]. In this study, we also found the ratio of Th17/Treg in refractory SLE group tended to be lower compared with that in healthy controls although there was no statistical
Fig. 1 FACS analysis of Th17 cells and Treg cells in the PBMCs of refractory SLE patients and healthy controls. 

(a) Representative flow cytometric analysis of human Th17 cells (CD4^{+} IL-17^{+}) isolated from healthy control and SLE patients; 

(b) Representative flow cytometric analysis of human Treg cells (CD4^{+} CD25^{+} Foxp3^{+}) isolated from healthy control and SLE patients; 

(c) The absolute number of Th17 cells and Treg cells; The ratio of Th17 cells /Treg cells. N_{SLE} = 50; N_{HC} = 70
significance. Furthermore, the lack of difference in Th17 cells between refractory SLE group and healthy control group, suggests that the reduction of Treg cells may be the primary reason for the imbalance of Th17/Treg cells in SLE patients, leading to the breakdown of autoimmune tolerance, contributing to the occurrence and development of SLE.

Since we have demonstrated that Th17/Treg imbalance is associated with the occurrence and development of SLE, we speculated that this may be associated with the disease index. In this study, we collected all the patients’ detailed characteristics, clinical and laboratory data to analyze their association with Th17/Treg imbalance. However, all results demonstrated that there is no significant correlation across the absolute number of Treg cells, Th17 cells, Th17/Treg ratio with disease duration, SLEDAI score and ESR. However, Qian Xing et al. found that Th17/Treg is related to SLEDAI scores [25]. The reason for this difference may be that we pay more attention to the remission of refractory SLE patients but the difference in disease activity has been overlooked. It has been reported that Th17 cells in the active stage of the disease were significantly higher than those in the control group, while Th17 cells in the non-active stage were not significantly different from those in the control group [27]. In our study, there were patients who maintained a low level of activity without continuous remission, leading to a lack of statistical difference in the results.

For the role of Th17/Treg imbalance in the occurrence and development of SLE, it is crucial to restore and maintain the balance. It is well known that the differentiation and amplification of Treg cells require the presence of IL-2, and IL-2 can induce Foxp3 expression [29, 30]. The level of IL-2 affects the immune tolerance mediated by Treg cells, while low dose of IL-2 can selectively activate Treg in T1D [4], HCV-induced vasculitis [5], GVHD [6, 7], alopecia areata [8] and SLE [31]. IL-2 can also inhibit the differentiation of Th17 cells by inhibiting the expression of RORγt through the activation of STAT5 [32]. Therefore, the treatment of low-dose IL-2 for SLE can restore the balance of Th17/regulatory T cells and achieve immune tolerance, which may alleviate the condition of SLE patients. Von Spee-Mayer C et al. treated five refractory SLE with low-dose IL-2 for 5 days and found that Treg were increased in all patients. However, the study did not discuss the long-term effects [13]. Humrich et al. applied IL-2 to treat a patient with refractory SLE patient resulting in the rapid alleviation of the patient’s condition. However, at 6th week, the patient condition worsened: the SLEDAI score increased to 10 while the number of Treg cells decreased [14]. The above findings suggest that IL-2 can increase the number of Treg cells to improve condition promptly in SLE patients, but this effect was tempory. This could be explained by the notion that IL-2 can also interact with surface receptors on different cells to activate a variety of signaling pathways. Also, the biological effects mediated by IL-2 can be influenced by the concentration, the environment and the surrounding inflammatory cells [29, 33, 34].

Rapamycin is originally recognized as an antifungal drug, Kurebayashi et al. [16] confirmed that rapamycin can form an immunosuppressive compound with FKBP-12 (immunosuppressive protein) in cells, which can bind mTORC1 and block the signal transduction of PI3K/AKT/mTOR pathways. This can reduce the expression of

Table 2

| group         | duration r | duration p | ESR r | ESR p | SLEDAI r | SLEDAI p |
|---------------|------------|------------|-------|-------|----------|----------|
| Th17          | 0.110      | 0.451      | 0.152 | 0.297 | -0.010   | 0.944    |
| Treg          | -0.231     | 0.110      | -0.269| 0.062 | -0.267   | 0.063    |
| Th17/Treg     | 0.267      | 0.064      | 0.236 | 0.103 | 0.001    | 0.992    |

Fig. 2

Effect of low-dose IL-2 combined with rapamycin on the populations of Th17 and Treg cells: a The number of Th17 cells; b The absolute number of Treg cells; c The ratio of Th17/Treg One-way analysis of variance (ANOVA) test was performed, and the pairwise comparison was conducted using the LSD test. N_{SLE} = 50
RORyt, inhibiting the differentiation of Th17 cells while enhancing the transcription activity of Foxp3, Treg differentiation and function [35]. Also, in vitro studies revealed that rapamycin blocked Stat3 activation and greatly reduced the number of IL-17 effector cells [36]. Rapamycin can also induce the production of iTreg cells [37] by inhibiting mTORC1 to enhance the Smad3 signaling pathway, promoting the proliferation and differentiation of Treg cells [38]. Thus, in some studies, Rapamycin was used to inhibit the differentiation of Th17 cells and promote the proliferation and differentiation of Treg cells in kidney transplant recipients [15], murine CD4+ T cell transfer model of colitis and an experimental autoimmune encephalomyelitis (EAE) model [16] and CCl4-induced liver fibrosis [17]. If IL-2 is used along with rapamycin to treat SLE, it is possible that this approach not only promotes an increase in the Treg population in SLE patients, but also overcomes the short-term effect. Th17 cells and Treg cells can reach a stable immune balance state, which can control the disease progression of SLE.

Based on the above studies, we adopted low-dose IL-2 in combination with rapamycin as a treatment for refractory SLE patients to analyze the numbers of Tregs and Th17 cells. Also, we observed the clinical indicators as well as the basic clinical medication to evaluate the drug efficacy in patients with refractory SLE. As for the dose of IL-2 and rapamycin, different studies utilized varying doses. However, most doses of IL-2 ranged from 1X10^5-3X10^6 IU/m^2/day while the dose of rapamycin is 2 mg/day without the report of adverse effects [8, 12, 15, 10]. In this study, we administered IL-2 with 100 WIU, 3-5d/month via subcutaneous injection to SLE patients and rapamycin with 0.5 mg, once every other day by oral administration. No serious adverse events were found. In addition, the number of Treg cells in patients treated with low-dose IL-2 combined with rapamycin at 12th and 24th week was significantly increased compared to 0 week. Humrich et al. only used IL-2 to observe that the number of Treg cells increased before 6 weeks, but decreased after 6 weeks. However, in our study, low-dose IL-2 combine with rapamycin could lead to an increase of Treg cells till the 24th week. Furthermore, the ratio of Th17/Treg was significantly lower at 24th week compared to that at 6th week, despite that there was no significant difference in the number of Th17 cells. Altogether, we conclude that the change in the Th17/Treg ratio is mainly caused by the change in the Treg population.
As for the clinical indicators, we observed that the SLEDAI gradually decreased after treatment. The SLEDAI score at 6th week and 12th week was lower than 0 week. After 6th week post treatment, the SLEDAI changed smoothly, which might account for the role of IL-2 but the maintenance mainly account for the use of rapamycin. Also, the SLEDAI at 24th week is $3.54 \pm 2.73$ suggesting that the disease is at the inactive stage. The SLEDAI scores at 0, 6th and 12th week are $5.95 \pm 2.63$, $4.84 \pm 1.98$ and $4.06 \pm 2.17$, which suggests that the disease is at the active stage. However, we didn’t find any difference in ESR at 0, 6th, 12th and 24th week, which indicates that ESR could be influenced by other factors.

It is well recognized that in severe cases of refractory SLE, large dose prednison or cytotoxic drugs are used to treat patients. However, current treatments also cause many side effects such as obesity, osteoporosis, gastric ulcer and infection. A combination of different drugs may not only alleviate disease but also decrease the dose of prednison or cytotoxic drugs, which will be beneficial to the patients. In this study, we found that a combination of low-dose IL-2 and rapamycin could reduce the dosage of prednison, which is beneficial due to the reduction of side effects. Although there was no difference in hydroxychloroquine (HCQ) and Mycophenolate Mofetil Capsules (MMF), we observed a declining trend in the dose of MMF. In the future, we will increase the sample size to reevaluate this finding.

The above findings suggest that low-dose IL-2 combined with rapamycin for the treatment of refractory SLE patients can increase the number of Treg, restore Th17/Treg balance, reduce disease activity and reduce the dose of prednison, which is beneficial for patients with refractory SLE.

Conclusion

In summary, our study has confirmed that the imbalance between Th17 cells and Treg cells caused by the significant reduction of Treg cells may be one of the major causes of SLE. Modulating the balance between Th17 cells and Tregs can be used as a potential approach for the treatment of SLE. We found that low dose of IL-2 combined with rapamycin significantly increased the number of Treg cells and restored the balance of Th17/Treg. This led to the alleviation of SLE symptoms, improvements in the rate of disease remission, and reduction in the dose of prednison. Although our study highlighted a new strategy to SLE treatment, future studies are needed to elucidate the mechanisms for how IL-2 and rapamycin synergistically enhance the Treg population long-term.

Abbreviations
ACR: American College of rheumatology; HC: Healthy controls; IL-2: Interleukin-2; PBMCs: Peripheral blood mononuclear cells; SLE: Systemic lupus erythematosus; SLEDAI: SLE disease activity index; Th17: T-helper 17 cells; Treg: Regulatory T cells

Acknowledgements

We would like to thank Dr. Jing Luo, Ms. Xiangcong Zhao and Mr. Chen Zhang from the laboratory of rheumatology and immunology, the second hospital of Shanxi medical university for generously donating their time and supporting flow cytometry. I would also like to thank professor Baqunj Zhang from Xi’an jiaotong university for editing the paper, and professor Chong Gao of harvard medical school for his support about research theory.

Authors’ contributions

CZ performed the majority of the experiments involving flow cytometry. ZL and YC also performed some of the experiments where T cells were stimulated with PMA and ionomycin. YC, ZL, BZ, XW, XJ, MH, YW, JA contributed to the data collection. CZ, YC, ZL and JC contributed to the data analysis. The manuscript was written by CZ and JC. The manuscript was edited by CZ, XZ, LS, and JC. The work was funded by grants obtained by JC. JC oversaw all work on this project. All authors have read and approved this manuscript.

Funding

This work was supported by the Natural Science Foundation of Shanxi Province(201701D121086). The content is solely the responsibility of the authors and does not necessarily represent the official views. The funding body was not involved in the design of the study, collection or analysis of the data, interpretation of the data, or in the writing of the manuscript.

Availability of data and materials
The majority of the data generated or analyzed during this study are included in this published article and its supplementary information files. Any other datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All research on humans was performed in accordance with the Declaration of Helsinki. All human subjects read and signed a consent form after being presented with an opportunity to ask questions related to the study. This study was conducted as approved by the Ethics committee, the Second hospital of Shanxi Medical University (The Efficacy and Safety of Low Dose IL-2 Combined Rapamycin Therapy in Chinese Over-treated Patients with Systemic Lupus Erythematosus, 2016KY-007,2016KY-015). The content is solely the responsibility of the authors and does not necessarily represent the official views. The funding body was not involved in the design of the study, collection or analysis of the data, interpretation of the data, or in the writing of the manuscript.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Rheumatology and Immunology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China. 2. School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an 710061, China. 3. Institute of Translational Medicine, The First Hospital of Jilin University, Changchun 130021, China.

Received: 25 January 2019 Accepted: 19 June 2019
Published online: 04 September 2019

References

1. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029.
2. Talaat RM, Mohamed SF, Bassiyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146–53.
3. Smyrykalaiczarek M, Kosmaczewa A, Ciszak L, Szbichel A, Wiland P. Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. Postepy Hig Med Dosw. 2014;68:893–8.
4. Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérain N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, et al. Low-dose interleukin-2 fosters a...
dose-dependent regulatory T cell tuned milieu in TID patients. J Autoimmun. 2015;58:48–58.
5. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alvey EP, 3rd, Armand P, Cutler C, Ho VT, Treister NS, et al. Interleukin-2 and regulatory T cells in graft‐versus‐host disease. N Engl J Med. 2011;365(22):2055–66.
6. Matsuoka KI. Low‐dose interleukin‐2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives. Int J Hematol. 2018;107(2):130–7.
7. Matsuoka KI, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alvey EP, et al. Low‐dose Interleukin‐2 therapy restores regulatory T cell homeostasis in patients with chronic graft‐versus‐host disease. Sci Transl Med. 2013;5(197):197ra94.
8. Castela E, Le Duft F, Butori C, Tichonni M, Hofmann P, Bahadoran P, Lacour JP, Passeron T. Effects of low‐dose recombinant interleukin 2 to promote T‐regulatory cells in alopoea areata. JAMA Dermatol. 2014;150(7):748–51.
9. Goupy K, Aydin D, Borzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, Doglioni C, Ponzoni M, Cicalese MP, Assanelli E, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol. 2013;146(3):268–71.
10. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfeder M, Rosenzweig M, Bernard C, Klatzmann D. Low‐dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295–305.
11. Saadoun D, Rosenzweig M, Joly F, Six A, Carant F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T‐cell responses to low‐dose interleukin‐2 in HCV‐induced vasculitis. N Engl J Med. 2011;365(22):2067–77.
12. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low‐dose interleukin 2 treatment selectively modulates CD4(+) T cell function in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–3.
13. von Spee‐Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Humrich JY, Von Spee‐Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G. Rapid induction of clinical remission by low‐dose interleukin‐2 in a patient with refractory SLE. Ann Rheum Dis. 2015;74(4):791–2.
14. Kim KW, Chung BH, Kim BM, Cho ML, Yang CW. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144(1):68–78.
15. Kurebayashi Y, Nagai S, Ikerei A, Ohtani M, Ichiyama K, Baba Y, Yamada T, Egami S, Hoshii T, Hirao A, et al. PI3K‐Akt‐mTORC1‐S6K1/2 axis controls Th17 differentiation by regulating GFI1 expression and nuclear translocation of RORγt. Cell Rep. 2012;1(6):360–70.
16. Gu L, Deng WS, Sun XF, Zhou H, Xu Q. Rapamycin ameliorates CCl4‐induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance. Mol Med Rep. 2016;14(2):1153–60.
17. Jing X, Gao C, Hao L, Hao M, Liang Z, Li XF, Chen J. Low‐dose IL‐2 combined with rapamycin efficiently promoted disease remission and recovered the balance of Th17/Treg regulatory T cells in patients with refractory systemic lupus erythematosus (abstract). Arthritis Rheumatol. 2018;70(suppl 10).
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
19. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lupus involvement. Lupus. 2009;18(9):767–73.
20. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008;93(5):401–6.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630–40.
22. Nie J, Li YY, Zheng SG, Tson A, Li B. FOXP3(+) Treg cells and gender Bias in autoimmune diseases. Front Immunol. 2015;6:493.
23. Zickert A, Amouzourni P, Sundström Y, Rinnelli J, Malmström V, Gunnarsson I. IL‐17 and IL‐23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16(1):7.
24. Qian X, Wang B, Cui J, Cui J, Li J. Elevated Th17 cells are accompanied by Foxp3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int. 2012;32(6):1499–508.
25. Noack M, Mossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimm Rev. 2014;13(6):668–77.
26. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472–83.
27. Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdullahah WH. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol. 2011;141(2):197–204.
28. Cheng G, Yu A, Dee MJ, Malek TR. IL‐2R signaling is essential for functional maturation of T regulatory cells during thymic development. J Immunol. 2013;190(4):1567–75.
29. Nazal D, Gradolatto A, Truffaut F, Bismuth J, Berrih‐Aknin S. Human thymus medullary epithelial cells promote regulatory T‐cell generation by stimulating interleukin‐2 production via ICOS ligand. Cell Death Dis. 2014;5(9):e1420.
30. Yu A, Snowhite I, Vendrame F, Rosenzweig M, Klatzmann D, Pugliese A, Malek TR. Selective IL‐2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low‐dose IL‐2 therapy in type 1 diabetes. Diabetes. 2015;64(6):2172–83.
31. Villarino A, Laurence A, Robinson GW, Bonelli M, Derna B, Afzal B, Shih HY, Sun HW, Brooks SR, Hennighausen L, et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. Elife. 2016;5.
32. Osnailde N, Sanchezquelles V, Akimov V, Guerra B, Blagoev B, Kratchmarova I. Simultaneous dissection and comparison of IL‐2 and IL‐15 signaling pathways by global quantitative phosphoproteomics. Proteomics. 2015;15(2):35–20.
33. Macintyre AN, Gerriets VA, Nichols AG, Michaelak RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20(1):61–72.
34. Basu S, Golovina T, Mkhieva T, June CH, Riley JL. Cutting edge: Foxp3‐mediated induction of Pim 2 allows human T regulatory cells to preferentially expand in rapsigam. J Immunol. 2008;180(9):5794–8.
35. Khirsagar S, Riedl M, Billing H, Tönshoff B, Thangavasidhal S, Steuber C, Staude H, Wechselberger G, Edebeauer M, Aftzal B, Shih HY, Sun HW, Brooks SR, Hennighausen L, et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. Elife. 2016;5.
36. Steinman LM, Sanchezquelles V, Akimov V, Guerra B, Blagoev B, Kratchmarova I. Simultaneous dissection and comparison of IL‐2 and IL‐15 signaling pathways by global quantitative phosphoproteomics. Proteomics. 2015;15(2):35–20.
37. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1‐arresting rapamycin‐receptor complex. Nature. 1994;369(6483):756–8.